ASCO and ESMO Absctracts

 Asco: Follow Up Of Lifileucel Treatment

Abstract No : 10006

Indication : Melanoma

Intervention : lifileucel (LN-144)

Company : Iovance Biotherapeutics, Inc.

Technology : TIL

Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant.

View More: https://www.delveinsight.com/asco-conference/article/lifileucel-LN-144

 

ASCO: Pegilodecakin

Abstract No : 9563

Abstract Type : Poster Session

Indication : PD-L1 selected NSCLC

Intervention : Pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P

Company : Eli Lilly and Company

Technology : Monoclonal antibody

Adding PEG to P did not lead to improvement in ORR, PFS, or OS, in 1L advanced NSCLC with high PD-L1 expression. PEG+P arm demonstrated expected safety profile but overall higher toxicity compared to pembrolizumab alone.

View More: https://www.delveinsight.com/asco-conference/article/NCT03382899

 

ASCO: Results from DREAMM-2 study

Abstract No : 8536

Abstract Type : Poster Discussion Session

Indication : Multiple Myeloma

Intervention : Belantamab mafodotin

Company : GlaxoSmithKline

Technology : BCMA Inhibitor

Belantamab mafodotin (GSK2857916) sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated RRMM. Being the first in class BCMA targeting ADC gives it a significant advantage over its competitors

View More: https://www.delveinsight.com/asco-conference/article/NCT03525678

 

ESMO Abstracts:

 

CheckMate 238 Results at ESMO 2020

Abstract No : Abstract: #1076O

Indication : Melanoma

Intervention : Nivolumab

Company : Bristol-Myers Squibb

Technology : PD-1/PD-L1 inhibitor

NIVO continued to demonstrate improved RFS and DMFS vs IPI at 48 mo in pts with stage III/IV melanoma at high risk of recurrence. OS events (n = 211) were lower than anticipated (n = 302). OS rates were similar to NIVO and IPI, although use of subsequent IO therapy was higher in the IPI arm. Late-emergent TRAEs were consistent with the established safety profile of NIVO and IPI, with more events reported with IPI.

View More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-238-NCT02388906-esmo-2020

 

CHRYSALIS study results at ESMO 2020

Abstract No : Abstract 1258O

Indication : Non-small cell lung cancer

Intervention : Amivantamab + lazertinib

Company : CHRYSALIS study

Technology : EGFR-MET bispecific antibody + TKI

Amivantamab (JNJ-61186372) can be combined safely with lazertinib at their respective full monotherapy doses. Encouraging preliminary activity was observed in osimertinib-relapsed disease

View More: https://www.delveinsight.com/esmo-conference-2020/article/chrysalis-study-NCT02609776-esmo-2020

 

PALLAS Trial: adjuvant palbociclib with endocrine therapy vs. endocrine therapy alone for HR+/HER2- early breast cancer

Abstract No : Presentation LBA12

Indication : Breast cancer

Intervention : Palbociclib

Company : Pfizer

Technology : CDK4/6 Inhibitor

Within the PALLAS trial, at IA2, two years of adjuvant palbociclib with ET did not improve iDFS compared to ET alone. Ongoing long-term follow-up and additional clinical and translational analyses will explore the effect of P in this patient population.

View More: https://www.delveinsight.com/esmo-conference-2020/article/PALLAS-pfizer-esmo-2020

About Delveinsight

DelveInsight is a leading Business Consultant, and Pharmaceutical Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t
Read more

Hypothalamic Obesity Market by DelveInsight

  (New York, USA) DelveInsight’s “ Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast-2032 ” report delivers an in-depth understanding of Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Hypothalamic Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hypothalamic Obesity market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hypothalamic Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hypothalamic Obesity market. Request for a Free Sample Report @  Hypothalamic Obesity Market Forecast Some facts of the Hypothalamic Obesity Market Report are: Accordi
Read more

Vernal Keratoconjunctivitis Market

(Albany, US) DelveInsight’s “ Vernal Keratoconjunctivitis Market  Insights, Epidemiology, and Market Forecast-2030 ” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key facts of the  Vernal Keratoconjunctivitis Market The increasing population and rising prevalence of Vernal Keratoconjunctivitis generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by Vernal Keratoconjunctivitis in the global market. China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total diagnosed prevalent population of Vernal Keratoconjunctivitis was 2,943,057 in the global market.   Request for Sample Report: https://www.delveinsight.com/report-store/vernal-kerato
Read more